Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for TCM Biotech International's PEG Ratio or its related term are showing as below:
During the past 13 years, TCM Biotech International's highest PEG Ratio was 511.68. The lowest was 53.98. And the median was 348.77.
TPE:4169's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.96 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
TCM Biotech International (TPE:4169) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
TCM Biotech International PEG Ratio Related Terms
TCM Biotech International PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4169 vs VRTX, REGN, RVMD: PEG Ratio Comparison
For the Biotechnology subindustry, TCM Biotech International's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's PEG Ratio distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
TCM Biotech International (TPE:4169) has a PEG Ratio of 0.00 as of Aug. 10, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on TCM Biotech International and its competitors. Over the past decade, TCM Biotech International's PEG Ratio has ranged from 53.98 to 511.68. According to the industry distribution chart, TCM Biotech International ranks #999999 out of 93 companies in the Biotechnology industry.
Is TCM Biotech International's PEG Ratio too high?
TCM Biotech International's current PEG Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 53.98 to a high of 511.68. Based on the distribution chart, TCM Biotech International ranks #999999 out of 93 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #999999 out of 93 companies for PEG Ratio. This places TCM Biotech International in the lower half of its industry. The industry median PEG Ratio is 1.96. Historically, TCM Biotech International's own PEG Ratio has ranged from 53.98 to 511.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.96, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current PEG Ratio is 0.00. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current PEG Ratio is 0.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
PEG Ratio: 0.00
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
